Latest papers

Potential molecular targets in chemopreventative action of celecoxib: a proteomics analysis of J774.A1 macrophage-like cell line.

Osteoprotegerin predicts progression of chronic heart failure: results from CORONA.

Resistance to BRAF inhibition in melanomas.

A cyclooxygase-2 inhibitor NS-398-enhanced apoptosis of esophageal carcinoma cell EC9706 by adjusting expression of survivin and caspase-3.

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.

Efficacy of brinzolamide ophthalmic suspension 1% for treatment of a vitelliform macular lesion in a patient with desferrioxamine retinopathy.

Funding linked to ongoing research: impact of the bosentan patient registry on pricing in Australia.

[Bringing evidence to practice: obstacles and barriers].

Inhibition of HERG potassium channels by celecoxib and its mechanism.

Thermodynamic aspects of solubility process of some sulfonamides.

Pre-steady-state kinetics of interaction of wild-type and multiple drug-resistant HIV protease with first and second generation inhibitory drugs.

Celecoxib can induce vascular endothelial growth factor expression and tumor angiogenesis.

[Zidena treatment of erectile dysfunction due to stress-induced arterial hypertension in locomotive teams].

Drug discovery: How melanomas bypass new therapy.

Drugs for kidney stones.

A pharmacokinetic and bioequivalence study of Contiflo ICON 400 µg tablets in healthy Indian subjects.

The roots of resistance.

Rosuvastatin reduces neointima formation in a rat model of balloon injury.

Role of leukotriene B4 in celecoxib-mediated anticancer effect

Rosuvastatin reduces microglia in the brain of wild type and ApoE knockout mice on a high cholesterol diet; implications for prevention of stroke and AD.